The first domestically-produced new crown drug approved: a dose of US$2,100 per dose, the Chinese price is undetermined-Economic Observer Network-Professional Financial News Website

Economic Observer Network reporter Qu Yixian On the evening of December 8, the State Food and Drug Administration urgently approved Tengshengbo Pharmaceutical (02137.HK)’s holding company Tengshenghua’s innovative coronavirus neutralizing antibody combination therapy drug Ambavirimab Injection (BRII-196) and Romi Application for registration of svirimab injection (BRII-198). This is China’s first self-developed new coronavirus-neutralizing antibody combination therapy […]